NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will hold its Annual Shareholders' Meeting (the "Meeting") on Monday, December 23, 2013 at 9:30 AM ET at the Sheraton Mahwah, 1 International Boulevard, Mahwah, NJ.

The Meeting will include an introduction, adjournment and Company overview provided by Kaushik J. Dave, President and Chief Executive Officer of Actinium.

The Proxy Statement, with the accompanying Notice of Annual Meeting, and 2012 Annual Report on Form 10–K are available on the "Investors" section of the Company's website at http://www.actiniumpharmaceuticals.com.

Shareholders of record of the Company's common stock at the close of business on November 7, 2013 will be entitled to receive notice of and to vote on matters discussed at the Meeting.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com  

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Email: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

SOURCE Actinium Pharmaceuticals, Inc.